1
|
El Moukhtari SH, Garbayo E, Amundarain A, Pascual-Gil S, Carrasco-León A, Prosper F, Agirre X, Blanco-Prieto MJ. Lipid nanoparticles for siRNA delivery in cancer treatment. J Control Release 2023; 361:130-146. [PMID: 37532145 DOI: 10.1016/j.jconrel.2023.07.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 07/08/2023] [Accepted: 07/30/2023] [Indexed: 08/04/2023]
Abstract
RNA-based therapies, and siRNAs in particular, have attractive therapeutic potential for cancer treatment due to their ability to silence genes that are imperative for tumor progression. To be effective and solve issues related to their poor half-life and poor pharmacokinetic properties, siRNAs require adequate drug delivery systems that protect them from degradation and allow intracellular delivery. Among the various delivery vehicles available, lipid nanoparticles have emerged as the leading choice. These nanoparticles consist of cholesterol, phospholipids, PEG-lipids and most importantly ionizable cationic lipids. These ionizable lipids enable the binding of negatively charged siRNA, resulting in the formation of stable and neutral lipid nanoparticles with exceptionally high encapsulation efficiency. Lipid nanoparticles have demonstrated their effectiveness and versatility in delivering not only siRNAs but also multiple RNA molecules, contributing to their remarkable success. Furthermore, the advancement of efficient manufacturing techniques such as microfluidics, enables the rapid mixing of two miscible solvents without the need for shear forces. This facilitates the reproducible production of lipid nanoparticles and holds enormous potential for scalability. This is shown by the increasing number of preclinical and clinical trials evaluating the potential use of siRNA-LNPs for the treatment of solid and hematological tumors as well as in cancer immunotherapy. In this review, we provide an overview of the progress made on siRNA-LNP development for cancer treatment and outline the current preclinical and clinical landscape in this area. Finally, the translational challenges required to bring siRNA-LNPs further into the clinic are also discussed.
Collapse
Affiliation(s)
- Souhaila H El Moukhtari
- Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain
| | - Elisa Garbayo
- Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain
| | - Ane Amundarain
- Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain; Hemato-Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Avenida Pío XII 55, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029, Madrid, Spain
| | - Simón Pascual-Gil
- Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain
| | - Arantxa Carrasco-León
- Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain; Hemato-Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Avenida Pío XII 55, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029, Madrid, Spain
| | - Felipe Prosper
- Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain; Hemato-Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Avenida Pío XII 55, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029, Madrid, Spain; Departmento de Hematología and CCUN, Clínica Universidad de Navarra, University of Navarra, Avenida Pío XII 36, 31008 Pamplona, Spain
| | - Xabier Agirre
- Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain; Hemato-Oncology Program, Center for Applied Medical Research (CIMA), University of Navarra, Avenida Pío XII 55, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029, Madrid, Spain
| | - María J Blanco-Prieto
- Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain.
| |
Collapse
|
2
|
Amundarain A, Pastor F, Prósper F, Agirre X. Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma. Cancers (Basel) 2022; 14:5471. [PMID: 36358889 PMCID: PMC9657029 DOI: 10.3390/cancers14215471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Revised: 10/31/2022] [Accepted: 11/04/2022] [Indexed: 08/30/2023] Open
Abstract
Multiple Myeloma (MM) remains an incurable disease due to high relapse rates and fast development of drug resistances. The introduction of monoclonal antibodies (mAb) has caused a paradigm shift in MM treatment, paving the way for targeted approaches with increased efficacy and reduced toxicities. Nevertheless, antibody-based therapies face several difficulties such as high immunogenicity, high production costs and limited conjugation capacity, which we believe could be overcome by the introduction of nucleic acid aptamers. Similar to antibodies, aptamers can bind to their targets with great affinity and specificity. However, their chemical nature reduces their immunogenicity and production costs, while it enables their conjugation to a wide variety of cargoes for their use as delivery agents. In this review, we summarize several aptamers that have been tested against MM specific targets with promising results, establishing the rationale for the further development of aptamer-based strategies against MM. In this direction, we believe that the study of novel plasma cell surface markers, the development of intracellular aptamers and further research on aptamers as building blocks for complex nanomedicines will lead to the generation of next-generation targeted approaches that will undoubtedly contribute to improve the management and life quality of MM patients.
Collapse
Affiliation(s)
- Ane Amundarain
- Center for Applied Medical Research (CIMA), IDISNA, University of Navarra, 31008 Pamplona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 31008 Pamplona, Spain
| | - Fernando Pastor
- Center for Applied Medical Research (CIMA), IDISNA, University of Navarra, 31008 Pamplona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 31008 Pamplona, Spain
| | - Felipe Prósper
- Center for Applied Medical Research (CIMA), IDISNA, University of Navarra, 31008 Pamplona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 31008 Pamplona, Spain
- Hematology Department, Clínica Universidad de Navarra, CCUN, University of Navarra, 31008 Pamplona, Spain
| | - Xabier Agirre
- Center for Applied Medical Research (CIMA), IDISNA, University of Navarra, 31008 Pamplona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 31008 Pamplona, Spain
| |
Collapse
|
3
|
Amundarain A, Valcárcel LV, Ordoñez R, Garate L, Miranda E, Cendoya X, Carrasco‐Leon A, Calasanz MJ, Paiva B, Meydan C, Mason CE, Melnick A, Rodriguez‐Otero P, Martín‐Subero JI, San Miguel J, Planes FJ, Prósper F, Agirre X. Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts. Am J Hematol 2022; 97:E113-E117. [PMID: 34961980 DOI: 10.1002/ajh.26450] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 12/06/2021] [Accepted: 12/20/2021] [Indexed: 12/31/2022]
Affiliation(s)
- Ane Amundarain
- Hemato‐Oncology Program, Center for Applied Medical Research (CIMA), IDISNA University of Navarra Pamplona Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
| | - Luis V. Valcárcel
- Hemato‐Oncology Program, Center for Applied Medical Research (CIMA), IDISNA University of Navarra Pamplona Spain
- Tecnun School of Engineering, Biomedical Engineering Center University of Navarra San Sebastian Spain
| | - Raquel Ordoñez
- Hemato‐Oncology Program, Center for Applied Medical Research (CIMA), IDISNA University of Navarra Pamplona Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
| | - Leire Garate
- Hemato‐Oncology Program, Center for Applied Medical Research (CIMA), IDISNA University of Navarra Pamplona Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
- Hematology Department, Clínica Universidad de Navarra University of Navarra Pamplona Spain
| | - Estíbaliz Miranda
- Hemato‐Oncology Program, Center for Applied Medical Research (CIMA), IDISNA University of Navarra Pamplona Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
| | - Xabier Cendoya
- Tecnun School of Engineering, Biomedical Engineering Center University of Navarra San Sebastian Spain
| | - Arantxa Carrasco‐Leon
- Hemato‐Oncology Program, Center for Applied Medical Research (CIMA), IDISNA University of Navarra Pamplona Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
| | - María José Calasanz
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
- CIMA LAB Diagnostics University of Navarra Pamplona Spain
| | - Bruno Paiva
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
- Hematology Department, Clínica Universidad de Navarra University of Navarra Pamplona Spain
- CIMA LAB Diagnostics University of Navarra Pamplona Spain
- Flow Cytometry Core, CIMA University of Navarra Pamplona Spain
| | - Cem Meydan
- Division of Hematology/Oncology, Department of Medicine Weill Cornell Medical College New York New York USA
- Department of Physiology and Biophysics Weill Cornell Medicine New York New York USA
- The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine Weill Cornell Medicine New York New York USA
| | - Christopher E. Mason
- Division of Hematology/Oncology, Department of Medicine Weill Cornell Medical College New York New York USA
- Department of Physiology and Biophysics Weill Cornell Medicine New York New York USA
- The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine Weill Cornell Medicine New York New York USA
| | - Ari Melnick
- Division of Hematology/Oncology, Department of Medicine Weill Cornell Medical College New York New York USA
| | - Paula Rodriguez‐Otero
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
- Hematology Department, Clínica Universidad de Navarra University of Navarra Pamplona Spain
| | - José I. Martín‐Subero
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
- Hospital Clínic de Barcelona and Departament de Fonaments Clínics, Facultat de Medicina Universitat de Barcelona Barcelona Spain
- Institut d'Investigacions Biomèdiques August Pi I Sunyer IDIBAPS Barcelona Spain
- Institució Catalana de Recerca i Estudis Avançats ICREA Barcelona Spain
| | - Jesús San Miguel
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
- Hematology Department, Clínica Universidad de Navarra University of Navarra Pamplona Spain
| | - Francisco J. Planes
- Tecnun School of Engineering, Biomedical Engineering Center University of Navarra San Sebastian Spain
| | - Felipe Prósper
- Hemato‐Oncology Program, Center for Applied Medical Research (CIMA), IDISNA University of Navarra Pamplona Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
- Hematology Department, Clínica Universidad de Navarra University of Navarra Pamplona Spain
| | - Xabier Agirre
- Hemato‐Oncology Program, Center for Applied Medical Research (CIMA), IDISNA University of Navarra Pamplona Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Pamplona Spain
| |
Collapse
|
4
|
Valcárcel LV, Amundarain A, Kulis M, Charalampopoulou S, Melnick A, San Miguel J, Martín-Subero JI, Planes FJ, Agirre X, Prosper F. Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. Leukemia 2021; 35:3012-3016. [PMID: 33972667 PMCID: PMC8478642 DOI: 10.1038/s41375-021-01263-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 04/08/2021] [Accepted: 04/26/2021] [Indexed: 02/06/2023]
Abstract
Clinical and genetic risk factors are currently used in multiple myeloma (MM) to stratify patients and to design specific therapies. However, these systems do not capture the heterogeneity of the disease supporting the development of new prognostic factors. In this study, we identified active promoters and alternative active promoters in 6 different B cell subpopulations, including bone-marrow plasma cells, and 32 MM patient samples, using RNA-seq data. We find that expression initiated at both regular and alternative promoters was specific of each B cell subpopulation or MM plasma cells, showing a remarkable level of consistency with chromatin-based promoter definition. Interestingly, using 595 MM patient samples from the CoMMpass dataset, we observed that the expression derived from some alternative promoters was associated with lower progression-free and overall survival in MM patients independently of genetic alterations. Altogether, our results define cancer-specific alternative active promoters as new transcriptomic features that can provide a new avenue for prognostic stratification possibilities in patients with MM.
Collapse
Affiliation(s)
- Luis V. Valcárcel
- grid.5924.a0000000419370271Area de Oncología, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, IDISNA, Pamplona, Spain ,grid.5924.a0000000419370271Tecnun School of Engineering, Universidad de Navarra, San Sebastian, Spain
| | - Ane Amundarain
- grid.5924.a0000000419370271Area de Oncología, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, IDISNA, Pamplona, Spain ,grid.510933.d0000 0004 8339 0058Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Pamplona, Spain
| | - Marta Kulis
- grid.428756.a0000 0004 0412 0974Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain ,grid.10403.36Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Stella Charalampopoulou
- grid.428756.a0000 0004 0412 0974Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain ,grid.10403.36Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - Ari Melnick
- grid.5386.8000000041936877XDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY USA
| | - Jesús San Miguel
- grid.5924.a0000000419370271Area de Oncología, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, IDISNA, Pamplona, Spain ,grid.510933.d0000 0004 8339 0058Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Pamplona, Spain ,grid.411730.00000 0001 2191 685XServicio de Hematología, Clínica Universidad de Navarra, Pamplona, Spain
| | - José I. Martín-Subero
- grid.510933.d0000 0004 8339 0058Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Pamplona, Spain ,grid.10403.36Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain ,grid.425902.80000 0000 9601 989XInstitució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain ,grid.5841.80000 0004 1937 0247Departamento de Fundamentos Clínicos, Universitat de Barcelona, Barcelona, Spain
| | - Francisco J. Planes
- grid.5924.a0000000419370271Tecnun School of Engineering, Universidad de Navarra, San Sebastian, Spain
| | - Xabier Agirre
- grid.5924.a0000000419370271Area de Oncología, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, IDISNA, Pamplona, Spain ,grid.510933.d0000 0004 8339 0058Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Pamplona, Spain
| | - Felipe Prosper
- grid.5924.a0000000419370271Area de Oncología, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, IDISNA, Pamplona, Spain ,grid.510933.d0000 0004 8339 0058Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Pamplona, Spain ,grid.411730.00000 0001 2191 685XServicio de Hematología, Clínica Universidad de Navarra, Pamplona, Spain
| |
Collapse
|